ADC Therapeutics (ADCT) Current Assets (2019 - 2026)
ADC Therapeutics (ADCT) posted Current Assets of $276.8 million for Q1 2026, down 9.65% sequentially from $306.3 million in Q4 2025, and up 7.28% YoY from $258.0 million in Q1 2025.
ADC Therapeutics (ADCT) Current Assets (2019 - 2026) Analysis & Trends
ADC Therapeutics has reported Current Assets for 8 years, with the latest figure at $276.8 million in Q1 2026.
- Quarterly Current Assets rose 7.28% year-over-year to $276.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $276.8 million (up 7.28% YoY) and the FY2025 annual result came in at $306.3 million, up 5.18% from the prior year.
- Current Assets declined to $276.8 million in Q1 2026 per ADCT's latest filing, from $306.3 million in the prior quarter.
- Over five years, Current Assets peaked at $487.7 million in Q1 2022 and troughed at $258.0 million in Q1 2025.
- A 5-year average of $353.3 million and a median of $336.3 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2024: Current Assets climbed 24.02% in 2022, then decreased 23.63% in 2024.
- Over 5 years, Current Assets stood at $435.0 million in 2022, then decreased by 22.69% to $336.3 million in 2023, then decreased by 13.39% to $291.3 million in 2024, then climbed by 5.18% to $306.3 million in 2025, then decreased by 9.65% to $276.8 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $276.8 million, $306.3 million, and $287.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | 261.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 261.71 Mn |
| Mar 31, 2026 | 276.77 Mn |
| Dec 31, 2025 | 306.34 Mn |
| Sep 30, 2025 | 287.15 Mn |
| Jun 30, 2025 | 318.76 Mn |
| Mar 31, 2025 | 257.99 Mn |
| Dec 31, 2024 | 291.25 Mn |
| Sep 30, 2024 | 333.01 Mn |
| Jun 30, 2024 | 355.36 Mn |
| Mar 31, 2024 | 290.21 Mn |
| Dec 31, 2023 | 336.29 Mn |
| Sep 30, 2023 | 375.60 Mn |
| Jun 30, 2023 | 412.81 Mn |
| Mar 31, 2023 | 380.01 Mn |
| Dec 31, 2022 | 434.98 Mn |
| Sep 30, 2022 | 438.10 Mn |
| Jun 30, 2022 | 424.44 Mn |
| Mar 31, 2022 | 487.71 Mn |
| Dec 31, 2021 | 525.18 Mn |
| Sep 30, 2021 | 568.41 Mn |